Welcome to our dedicated page for Neumora Therapeutics news (Ticker: NMRA), a resource for investors and traders seeking the latest updates and insights on Neumora Therapeutics stock.
Neumora Therapeutics, Inc. (Nasdaq: NMRA) is a clinical-stage biopharmaceutical company that regularly reports updates on its pipeline of seven programs targeting novel mechanisms of action for brain diseases and other underserved, prevalent diseases. News about Neumora often centers on clinical trial progress, preclinical data, financial results and corporate presentations, giving investors and observers insight into how its development strategy is unfolding.
Recent press releases highlight multiple areas of activity. The company has reported positive Phase 1b results for NMRA-511, an oral, highly potent, brain-penetrant and selective vasopressin 1a receptor antagonist being evaluated for agitation associated with Alzheimer’s disease. It has also provided frequent updates on navacaprant, a kappa opioid receptor antagonist in Phase 3 KOASTAL studies for major depressive disorder, including plans for consolidated topline readouts.
Neumora’s news flow also covers its M4 muscarinic receptor positive allosteric modulator franchise, with Phase 1 SAD/MAD studies of NMRA-861 and NMRA-898 designed to assess safety, tolerability and pharmacokinetics in healthy adults and people with stable schizophrenia. In addition, the company has announced preclinical diet-induced obesity data for NMRA-215, a highly brain-penetrant oral NLRP3 inhibitor prioritized for obesity, and has outlined plans to move this program into clinical testing.
Beyond scientific and clinical milestones, Neumora issues regular quarterly financial results, business updates and notices of participation in healthcare and investor conferences. The NMRA news page on Stock Titan aggregates these announcements so readers can follow developments in Alzheimer’s disease agitation, major depressive disorder, schizophrenia, obesity and other areas where Neumora is active.
Summary not available.